EXEVIR BIO
ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections. The company is harnessing a llama-derived antibody technology platform to generate robust antiviral therapies providing broad protection against coronaviruses. They using a highly innovative and clinically validated VHH technology to develop treatments for viral infections that may pose a significant global threat. ExeVir Bio develops a rapid response platfor... m for antivirals. This platform technology enables an agile response to new health threats thanks to its short throughput time to generate drug candidates. The resulting protein-based therapeutics are sufficiently stable and easy to produce at a reasonable cost to enable true global access. ExeVir Bio was founded in 2020 and is headquartered in Zwijnaarde, Belgium.
EXEVIR BIO
Social Links:
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2020-01-01
Address:
Zwijnaarde, Oost-Vlaanderen, Belgium
Country:
Belgium
Website Url:
http://www.exevir.com
Total Employee:
1+
Status:
Active
Contact:
750-495-334
Total Funding:
42 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Legendairy Foods
Formo is a cell-ag company that develops animal-free dairy products using nature-identical milk proteins from precision fermentation.
Current Advisors List
Current Employees Featured
Founder
Investors List
SFPI-FPIM
SFPI-FPIM investment in Series A - ExeVir Bio
Fund+
Fund+ investment in Series A - ExeVir Bio
Vives Louvain Technology Fund
Vives Louvain Technology Fund investment in Series A - ExeVir Bio
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series A - ExeVir Bio
Sambrinvest
Sambrinvest investment in Series A - ExeVir Bio
UCB Ventures
UCB Ventures investment in Series A - ExeVir Bio
V-Bio Ventures
V-Bio Ventures investment in Series A - ExeVir Bio
VIB
VIB investment in Series A - ExeVir Bio
S.R.I.W.
S.R.I.W. investment in Series A - ExeVir Bio
Official Site Inspections
http://www.exevir.com Semrush global rank: 4.5 M Semrush visits lastest month: 2.39 K
- Host name: 5.134.5.23.static.hosted.by.combell.com
- IP address: 5.134.5.23
- Location: Merelbeke Belgium
- Latitude: 51.0015
- Longitude: 3.7433
- Timezone: Europe/Brussels
- Postal: 9820
More informations about "ExeVir Bio"
Our team_ - ExeVir
Professor Xavier Saelens, scientific founder of Exevir is a Group Leader at the VIB-UGent Center for Medical Biotechnology at VIB and a full Professor Molecular Virology at Ghent University. …See details»
Our Company - ExeVir
ExeVir is a clinical stage company, able to fast-track drug development using our modular VHH platform. Our first candidate drug progressed from research to the clinical in less than 1 year. …See details»
ExeVir Bio - Crunchbase Company Profile & Funding
ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections. The company is …See details»
ExeVir Company Profile 2024: Valuation, Funding
What is the size of ExeVir? ExeVir has 19 total employees. What industry is ExeVir in? ExeVir’s primary industry is Drug Discovery. Is ExeVir a private or …See details»
ExeVir - LinkedIn
Exevir Bio is a biotech company developing efficacious heavy chain-only antibodies to prevent and treat infectious diseases and make a difference in pandemic preparedness.See details»
ExeVir Bio - Funding, Financials, Valuation & Investors - Crunchbase
ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections. Search Crunchbase. ... How much funding has this …See details»
ExeVir Bio - Devex
ExeVir is a clinical stage company developing single-domain antibody-based therapies that help patients ward off viral infections. Their lead candidate XVR011 is in accelerated development …See details»
Belgium: ExeVir lands European venture debt financing …
Jan 9, 2023 The European Investment Bank (EIB) and ExeVir BIO BV (ExeVir) have signed a €25 million venture debt financing agreement to advance the development of ExeVir’s novel COVID-19 therapeutic. The financing is part of …See details»
Board of directors - ExeVir
Chair of the Board & Interim CEO. Professor Michel Kazatchkine, joining as an independent director, brings over 35 years of experience in global health and has played key roles in various organizations, serving as Director of the National …See details»
ExeVir Announces Close of US$50 million / EUR42 million ... - PR …
GHENT, Belgium, March 16, 2021 /PRNewswire/ -- ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it …See details»
Phase I clinical study evaluates safety and pharmacokinetics of …
Aug 19, 2021 The randomized, double-blinded, single-center, placebo-controlled Phase I clinical study will evaluate the safety profile and pharmacokinetics of XVR011 administered as an IV …See details»
ExeVir Q&A: the llama-derived antibody that could fight Covid-19
Sep 6, 2021 ExeVir, which was spun out from the Flanders Institute for Biotechnology, has moved its lead candidate from laboratory tests to human clinical trials at an impressive pace, …See details»
ExeVir and Mithra announce manufacturing collaboration for …
Jul 15, 2021 Torsten Mummenbrauer, CEO of ExeVir Bio, said: "We are very pleased to collaborate with Mithra which has built a cutting-edge new fill and finish manufacturing facility. …See details»
ExeVir Bio Announces Positive Virus Neutralization Data for
Jan 15, 2024 ExeVir is a spin out of VIB, the leading Belgium-based life sciences research institute. It is backed by strong investors including Fund+, which led the series A of EUR 42 …See details»
ExeVir Bio Announces Positive Virus Neutralization Data for …
Jan 15, 2024 Can provide protection for millions of immuno-compromised and elderly who are most vulnerable to COVID-19GHENT, Belgium, Jan. 15, 2024 (GLOBE NEWSWIRE) -- ExeVir …See details»
Pipeline - ExeVir
ExeVir is doing its part to tackle the growing impact of infectious diseases by building a progressive pipeline of therapies that will help protect and treat the most vulnerable patients in …See details»
ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical …
Sep 1, 2021 ExeVir Bio is a clinical stage company harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including …See details»
Technology - ExeVir
MEDVIA article featuring ExeVir - Based on the interview with CSO, Viki Bockstal. By Amy LeBlanc. Images: Winter the llama ©Tim Coppens Ultrapotent SARS coronavirus-neutralizing …See details»
ExeVir announces first subjects dosed in Phase I clinical study of ...
Aug 18, 2021 ExeVir Bio Fiona du Monceau, COO Email: [email protected] Optimum Strategic Communications Mary Clark, Stella Lempidaki, Zoe Bolt Tel: +44 (0) 20 950 9144 Email: …See details»